NCT07544654 2026-04-22
A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Not yet recruiting
Boehringer Ingelheim
Jiangsu HengRui Medicine Co., Ltd.
Rezolute
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ITM Solucin GmbH
RayzeBio, Inc.